Real-time detection of T cell activity and classification through CD3 staining and AI technology is something that current equipment and techniques have yet to achieve. With this advancement, doctors can instantly assess a patient's immune cell activity during consultations, enabling them to provide the most effective cancer treatments. It also enhances the efficiency of quality control in the cell therapy industry. The cost is less than one-tenth that of existing technologies, with an accuracy rate of 94% for cell identification and 95% for activity detection.